Literature DB >> 9467964

Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis.

A Kangas1, D W Nicholson, E Hölttä.   

Abstract

c-Myc is a transcriptional activator implicated in the control of cell proliferation, differentiation and transformation, but is also involved in the regulation of programmed cell death, apoptosis. Despite intensive research, the molecular mechanisms by which c-Myc triggers and executes cell death remain still elusive. Here, we made use of Rat 1A MycER cells expressing a conditionally active c-Myc protein and tested first the hypothesis that ornithine decarboxylase (ODC), which is a transcriptional target of c-Myc, were a mediator of c-Myc-induced apoptosis. However, our results show that the activity of ODC is not required for the c-Myc-mediated apoptosis to occur in these cells. We also found that the expression of p53, p21waf1/cip1, Bcl-2, Bax, Bcl-xL, Bad and cyclins D1, E, A and B did not show any significant changes following c-Myc induction. But, our studies revealed that the c-Myc induced apoptosis is associated with a specific cleavage of poly(ADPribose) polymerase (PARP), suggesting that a cysteine protease of the ICE/CED-3 family is involved. Moreover, we found that the cysteine protease CPP32/Caspase-3, which is known to cleave PARP, is processed from its inactive form to an active protease composed of 17 and 12 kDa subunits; whilst Ich-1/Caspase-2 belonging to another subset of this protease family was not processed/ activated following c-Myc activation. The activation of CPP32 and apoptotic cell death were inhibited by addition of Z-VAD-fmk, a universal inhibitor of ICE-like proteases. Further, a selective inhibitor of CPP32-like proteases (Z-DEVD-fmk) partly inhibited apoptosis. These results provide evidence that the ICE/CED3-family proteases, CPP32 and likely others, play a critical role in the execution of a nuclear proto-oncogene, c-Myc-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467964     DOI: 10.1038/sj.onc.1201779

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation.

Authors:  R G Deschesnes; J Huot; K Valerie; J Landry
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

2.  Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators.

Authors:  K Kim; K M Pang; M Evans; E D Hay
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 3.  Multifunctional drug treatment in neurotrauma.

Authors:  Bogdan Stoica; Kimberly Byrnes; Alan I Faden
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

4.  Apoptosis and autophagy in polycystic kidney disease (PKD).

Authors:  Kristen L Nowak; Charles L Edelstein
Journal:  Cell Signal       Date:  2019-12-24       Impact factor: 4.315

5.  Escherichia coli enterotoxin B subunit triggers apoptosis of CD8(+) T cells by activating transcription factor c-myc.

Authors:  M Soriani; N A Williams; T R Hirst
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma.

Authors:  Alan C Taylor; Katja Schuster; Pamela P McKenzie; Linda C Harris
Journal:  Mol Cancer       Date:  2006-11-02       Impact factor: 27.401

7.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.

Authors:  M Volm; R Koomägi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

8.  Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7.

Authors:  M C Kamradt; N Mohideen; E Krueger; S Walter; A T Vaughan
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.

Authors:  Alison Roos; Laura Satterfield; Shuying Zhao; Daniel Fuja; Ryan Shuck; M John Hicks; Lawrence A Donehower; Jason T Yustein
Journal:  Br J Cancer       Date:  2015-10-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.